drugset / Trial / NCT07694700

Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.

NCT07694700

Phase 4 Active not recruiting 100 enrolled Beni-Suef University
RandomizedParallel-groupOpen-labelTreatment

Summary

Objective of this study is to compare the efficacy and safety between combination of colistin and meropenem and combination of amikacin and meropenem for multi-drug-resistant gram-negative bacteria in Intensive Care Unit. In Beni- Suef University Hospital.

Timeline

Start
2025-12-30
Primary completion
2026-08-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amikacin Small molecule 15 mg/kg Intravenous
Comparator Amikacin Small molecule 30 mg/kg Intravenous
Comparator Colistimethate Unknown 2.5 mg/kg Intravenous
Comparator Colistimethate Unknown 5 mg/kg Intravenous
Comparator Meropenem Small molecule 2 g Intravenous